Clicky

The publisher’s final edited version of this article is available at Biomaterials See other articles in PMC that cite the published article. Oncolytic human herpes simplex virus type 1 (HSV-1) shows promising treatment efficacy in late-stage clinical trials. Delivery of viral vectors to tumors in the brain is a challenge, especially via systemic administration, which is key to targeting the invasive margins of malignant glioma and the multiple foci of metastatic disease. Triple-negative breast cancers (TNBCs) have poor clinical outcomes owing to a lack of targeted therapies. Breast cancers especially in the late and metastatic stages remain refractory to treatment despite advances in surgical techniques and chemotherapy. Herpes simplex virus (HSV) pneumonia may be a life-threatening infection infrequently reported in patients with impaired cellular immunity, such as critically ill and/or immunocompromised patients1–3; patients with lymphoreticular malignancies,4, 5 human immunodeficiency virus (HIV) infection,5–8 leukemia,7 or burns8–10; those who have undergone organ or hematopoietic stem cell transplantation (HSCT)5, 11–13; or those who have received cytotoxic or immunosuppressive agents.5, 7, 8 HSV pneumonia has been rarely reported in patients with solid tumors; to our knowledge, the clinical significance of HSV in lower respiratory tract specimens (LRTS) and the importance of these infections remains unknown in this patient population. This is a short preview of the document.


Studies evaluating the presence of viral sequences in breast cancer (BC), including various strains of human papillomavirus and human herpes virus, have yielded conflicting results. The herpes virus and its behavior, both in individuals and in our society, is a direct reflection of our unexamined beliefs and fears. To determine whether HCMV was present in breast epithelium from normal controls and breast cancer patients, archived formalin fixed paraffin embedded breast tissues were utilized. Mammosphere cells were analyzed by flow cytometry. Mouth ulcers can pose quite a few problems, being painful every time you have to taken in something through the mouth. Angiogenin (ANG) is a 14-kDa multifunctional proangiogenic secreted protein whose expression level correlates with the aggressiveness of several tumors. Treato does not review third-party posts for accuracy of any kind, including for medical diagnosis or treatments, or events in general.

Kaposi’s sarcoma (KS) is a rare form of cancer that causes purple blotchy marks on the skin. Abstract:Triple-negative breast cancers (TNBCs) have poor clinical outcomes owing to a lack of targeted therapies. WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health. There have been reports of osseous metaplasia, or bone formation, in diverse malignancies, including the colon, the lung, the gastrointestinal tract, the thyroid, the breast and the pancreas from as early as 1923.1, 2 Though a rare occurrence, tumors that naturally calcify decelerate in growth rate.3 This observation led to an entire line of research that has resulted in isolation and understanding of a number of protein factors that govern bone formation.1, 4 One of the most interesting of these proteins is bone morphogenetic protein 2 (BMP-2), a cytokine factor sequenced in 1993.5 BMP-2 is one of the 30 identified bone morphogenetic proteins,4 and has been found to regulate the differentiation of uncommitted cells along osteoblastic pathways.6 It is a 115-amino acid protein that was identified for its ability to recruit mesenchymal stem cells and promote the differentiation of these stem cells to form bone.5 In addition to the osteoinductive properties of BMP-2, in recent years this protein has been found to exact inhibitory effects on the growth of certain tumors.7, 8, 9 We predicted that we could deliver this protein to tumor cells as a strategy for specifically retarding tumor cell growth and inducing heterotopic ossification. A study found a link between EBV, CMV, HSV, and breast cancer. A potentially novel therapeutic strategy for breast cancer treatment involves sensitization of tumor cells to chemotherapy through gene transfer. Oncolytic herpes simplex virus vectors are a promising strategy for cancer therapy, as direct cytotoxic agents, inducers of antitumor immune responses, and as expressers of anticancer genes.

Improving Oncolytic Herpes Simplex Virus for Metastatic Breast Cancer on ResearchGate, the professional network for scientists. In this study, the growth of locally disseminated breast cancer was modeled using a human breast cancer cell line, MDA-MB-435A, adapted to grow as an ascites tumor in athymic mice. more behavior observed in this population are grouped into well known form of psychiatric syndromes, or if the presentations are atypical. Scientists believe they have established a link between poverty and mutation of a gene which could explain why women from poorer backgrounds are less likely to survive breast cancer. Hurst DR (2014) Histone Deacetylase Inhibitors Improve the Replication of Oncolytic Herpes Simplex Virus in Breast Cancer Cells. Background: CD44+CD24−/low is an important marker of breast cancer stem cells, which underlies the incurable and relapse characteristics of breast cancer in clinic. WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.